CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosisFelix Fischbach, Nicolaus Kröger, Kristin Rathje et al.|Med|2024Cited by 161
Current state and perspectives of CAR T cell therapy in central nervous system diseasesLena Kristina Pfeffer, Manuel A. Friese, Felix Fischbach et al.|Brain|2024Cited by 12
CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple SclerosisJohanna Richter, Nicolaus Kroeger, Felix Fischbach et al.|Blood|2024Cited by 9
Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic reviewBente Braun, Vivien Häußler, Felix Fischbach et al.|European Journal of Neurology|2024Cited by 6
Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of lifeBente Braun, Vivien Häußler, Felix Fischbach et al.|Multiple Sclerosis and Related Disorders|2023Cited by 5